Pancreatic Cancer News
Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Durvalumab plus tremelimumab added to chemotherapy did not improve survival or response in metastatic pancreatic cancer, according to results of a phase 2 trial.
Using cohorts from 2 large observational studies, researchers investigated whether duration of diabetes and extent of weight loss may be a marker of risk for pancreatic cancer.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Zenocutuzumab is a first-in-class bispecific antibody that binds to HER2 and HER3 receptors, thereby blocking the interaction of HER3 with its ligand neuregulin 1 (NRG1) or NRG1-fusion proteins.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
The NALIRIFOX chemotherapy regimen includes liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Neoadjuvant treatment with GEMCAP, FOLFIRINOX, or capecitabine plus radiotherapy prolonged OS compared with immediate surgery in patients with pancreatic cancer.
The study results suggest that patients with weight loss after age 50 years in the context of new-onset type 2 diabetes may be good candidates for pancreatic cancer screening.
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Area under the ROC curve estimated by cross-validation was 0.62 for multifactor model.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
In the management of PNETs it is important to differentiate between functional and nonfunctional PNETs in order to determine the course of treatment.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.